NOVEL OPHTHALMIC COMPOSITIONS

• US 20130267591A1
• Filed: 05/06/2011
• Published: 10/10/2013
• Est. Priority Date: 05/07/2010
• Status: Abandoned Application

• Current Assignee: Sun Pharma Advanced Research Company Limited (Shanghvi Finance Pvt Ltd.)
• Original Assignee: Sun Pharma Advanced Research Company Limited (Shanghvi Finance Pvt Ltd.)
• Inventors: Khopade, Ajay Jaysingh, Halder, Arindam, Bhowmick, Subhas Balaram
• Application Number:
  US13/696,685
• Publication Number:
  US 20130267591A1
• Time in Patent Office: Days
• US Class Current: 514/530
• CPC Class Codes: A61K 31/216 of acids having aromatic rings, e.g. benactizyne, clofibrate
• CPC Class Codes: A61K 31/5377 not condensed and containing further heterocyclic rings, e.g. timolol
• CPC Class Codes: A61K 31/557 Eicosanoids, e.g. leukotrienes or prostaglandins
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 47/02 Inorganic compounds
• CPC Class Codes: A61K 47/10 Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• CPC Class Codes: A61K 47/12 Carboxylic acids; Salts or anhydrides thereof
• CPC Class Codes: A61K 47/186 Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
• CPC Class Codes: A61K 47/32 Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers , poly(meth)acrylates, or polyvinyl pyrrolidone
• CPC Class Codes: A61K 47/38 Cellulose; Derivatives thereof
• CPC Class Codes: A61K 47/44 Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61K 9/08 Solutions composition of solutions A61K47/00
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics

Abstract

An ophthalmic solution comprising therapeutically effective amount of a prostaglandin or its analog and water soluble excipient(s) dissolved in a pharmaceutically acceptable vehicle, wherein the solution is free of a surfactant.

Claims

1. An ophthalmic solution comprising therapeutically effective amount of a prostaglandin or its analog and water soluble excipient(s) dissolved in a pharmaceutically acceptable vehicle, wherein the solution is free of a surfactant.

2. An ophthalmic solution as claimed in claim 1 further comprises a beta adrenergic blocking agent.

3. An ophthalmic solution as claimed in claim 1 wherein water soluble excipient(s) are water soluble polymer or one or more penetration enhancing agents.

4. An ophthalmic solution as claimed in claim 1 wherein the solution is free of preservatives which are organic mercurial compounds, quaternary ammonium compound or substituted alcohol or phenol.

5. An ophthalmic solution as claimed in claim 3 wherein the solution is stored in a parylene coated plastic bottle.

8. A method of treating glaucoma or ocular hypertension which comprises topically administering to an affected eye an ophthalmic solution defined by claim 1.

9. A method of treating glaucoma or ocular hypertension which comprises topically administering to an affected eye an ophthalmic solution defined by claim 2.

10. A method of treating glaucoma or ocular hypertension which comprises topically administering to an affected eye an ophthalmic solution defined by claim 3.

11. A method of treating glaucoma or ocular hypertension which comprises topically administering to an affected eye an ophthalmic solution defined by claim 4.

12. A method of treating glaucoma or ocular hypertension which comprises topically administering to an affected eye an ophthalmic solution defined by claim 5.

6. An ophthalmic solution consisting essentially of therapeutically effective amount of a prostaglandin or its analog, co-solvent(s) and self preserving system and optionally, pharmaceutically acceptable excipients selected from the group consisting of viscosity enhancing agents and buffers.

7. An ophthalmic solution as claimed in claim 6 wherein viscosity enhancing agents is a water soluble polymer.

13. A method of treating glaucoma or ocular hypertension which comprises topically administering to an affected eye an ophthalmic solution defined by claim 6.

14. A method of treating glaucoma or ocular hypertension which comprises topically administering to an affected eye an ophthalmic solution defined by claim 7.